Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer.
Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer.
复制标题
初始 LDH 水平可以预测贝伐珠单抗一线治疗中国转移性结直肠癌患者的生存获益
DOI：
10.2147/ott.s64559
复制
发表时间：
2014
影响因子：
4
通讯作者：
Xia L
中科院分区：
文献类型：
--
作者：
Yin C;Jiang C;Liao F;Rong Y;Cai X;Guo G;Qiu H;Chen X;Zhang B;He W;Xia L
预测贝伐单抗治疗效果的标志物在大多数癌症中尚未得到充分验证，包括转移性结直肠癌（mCRC）。本研究的目的是在中国mCRC患者中研究乳酸脱氢酶（LDH）在预测一线贝伐珠单抗治疗的生存获益中的潜在作用。方法收集2003 - 2013年中山大学附属肿瘤防治中心确诊的mCRC患者的临床资料。根据是否接受贝伐单抗将研究组和对照组进行分类。所有患者在一线治疗前均检测血清LDH值。主要终点是无进展生存期（PFS）。结果研究组和对照组的中位PFS分别为11.3和9.1个月（P=0.004）。对照组中，LDH高水平组和LDH低水平组的中位PFS分别为6.9和10.2个月（P<0.001）。然而，在研究组中，相应的中位PFS分别为9.9和11.9个月（P=0.145）。此外，在低LDH水平组中，接受或未接受贝伐珠单抗治疗的患者的中位PFS分别为11.9和10.2个月（P=0.066）;然而，在高LDH水平组中，接受或未接受贝伐珠单抗治疗的患者的中位PFS存在显著差异（分别为9.9和6.9个月）（P=0.012）。结论贝伐珠单抗一线治疗可显著改善mCRC患者的PFS。然而，仅在血清LDH水平高的患者中可能反映出获益。
Background Markers to predict the efficacy of bevacizumab treatment have been not fully validated in most cancers, including metastatic colorectal cancer (mCRC). The aim of this study was to investigate the potential role of lactate dehydrogenase (LDH) in predicting the survival benefit from first-line bevacizumab treatment, in Chinese patients with mCRC. Methods All the patients were diagnosed with mCRC at the Sun Yat-sen University Cancer Center from 2003 to 2013. The study group and the control group were classified by receiving bevacizumab or not. The serum LDH value of all the patients had been detected before the first-line treatment. The primary end point was progression-free survival (PFS). Results The median PFS of the study and the control group (patients who received bevacizumab or not) was 11.3 and 9.1 months, respectively (P=0.004). In the control group, the median PFS of the high LDH level and the low LDH level groups was 6.9 and 10.2 months, respectively (P<0.001). However, in the study group, the corresponding median PFS was 9.9 and 11.9 months, respectively (P=0.145). In addition, for the low LDH level group, the median PFS was 11.9 and 10.2 months for patients who received bevacizumab or not, respectively (P=0.066); however, the median PFS of patients receiving bevacizumab or not was significantly different in the high LDH level group (9.9 and 6.9 months, respectively) (P=0.012). Conclusion The addition of bevacizumab in the first-line treatment setting could improve the PFS of mCRC patients notably. However, the benefit could only be potentially reflected on patients with high serum LDH level.